Journal: Cells

Article Title: Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3

doi: 10.3390/cells8030270

Figure Lengend Snippet: Therapeutic agents for the inhibition of VEGF-C/VEGFR3 signaling.

Article Snippet: Vandetanib , Small molecule TKI (VEGFRs, PDGFRs, EGFR, RET) , AstraZeneca , Phase II , [ , ] .

Techniques: Inhibition

Journal: Medicine

Article Title: Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs

doi: 10.1097/MD.0000000000032169

Figure Lengend Snippet: Basic characteristics of included literature.

Article Snippet: Kanglaite combined with erlotinib/icotinib , 2 , P = .87, I 2 = 0% , 1.25 (1.03–1.51) , .02.

Techniques:

Journal: Medicine

Article Title: Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs

doi: 10.1097/MD.0000000000032169

Figure Lengend Snippet: Subgroup analysis of ORR.

Article Snippet: Kanglaite combined with erlotinib/icotinib , 2 , P = .87, I 2 = 0% , 1.25 (1.03–1.51) , .02.

Techniques:

Journal: Medicine

Article Title: Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs

doi: 10.1097/MD.0000000000032169

Figure Lengend Snippet: Subgroup analysis of DCR.

Article Snippet: Kanglaite combined with erlotinib/icotinib , 2 , P = .87, I 2 = 0% , 1.25 (1.03–1.51) , .02.

Techniques:

Journal: Expert opinion on emerging drugs

Article Title: Emerging drugs to treat squamous cell carcinomas of the head and neck

doi: 10.1517/14728214.2010.497754

Figure Lengend Snippet: Selected agents that are currently in clinical trials are represented here. Briefly, EGFR and VEGFR signals utilize a variety of downstream molecular pathways including the PI3K-Akt-mTOR, STAT and Ras-MAPK (ERK) pathways. Agents targeting these pathways include mAbs (cetuximab, panitumumab, necitumumab, ch806, bevacizumab), tyrosine kinase inhibitors (erlotinib, gefitinib, vandetanib, lapatinib), multikinase inhibitors (sorafenib, sunitinib), Src family kinase inhibitors (dasatinib, saracatinib), mTOR inhibitors (everolimus, temsirolimus) and nucleic acid decoy (STAT3 decoy). p53 and Rb are tumor suppressors that are inhibited by HPV proteins E6 and E7, respectively. E6 and E7 are constitutively expressed in HPV-16 and -18 infected tumor cells and are targeted by HPV peptide vaccines. Vaccination against E6 and E7 allows cytotoxic T-cell recognition of infected cells.

Article Snippet: Vandetanib , Angiogenesis, VEGFR, EGFR , TKI specific for VEGFR and EGFR , AstraZeneca , Phase II.

Techniques: Clinical Proteomics, Infection, Vaccines

Journal: Expert opinion on emerging drugs

Article Title: Emerging drugs to treat squamous cell carcinomas of the head and neck

doi: 10.1517/14728214.2010.497754

Figure Lengend Snippet: Selected EGFR targeted therapies.

Article Snippet: Vandetanib , Angiogenesis, VEGFR, EGFR , TKI specific for VEGFR and EGFR , AstraZeneca , Phase II.

Techniques:

Journal: Expert opinion on emerging drugs

Article Title: Emerging drugs to treat squamous cell carcinomas of the head and neck

doi: 10.1517/14728214.2010.497754

Figure Lengend Snippet: Selected targeted therapies in clinical development for HNSCC.

Article Snippet: Vandetanib , Angiogenesis, VEGFR, EGFR , TKI specific for VEGFR and EGFR , AstraZeneca , Phase II.

Techniques:

Journal: Anti-cancer drugs

Article Title: Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase targeted therapy in lung and gastric cancer

doi: 10.1097/CAD.0000000000000561

Figure Lengend Snippet: Induction of Bcl-2 and Bcl-xL by TKIs in RTK-dependent lung and gastric cancer cell lines. EGFR-dependent lung cancer cell lines HCC827, PC9, and HCC4006 (A), ALK-dependent lung cancer cell line H3122, and HER2-dependent gastric cancer cell line NCI-N87 were treated with gefitinib (1 μM), gefitinib (0.2 μM), erlotinib (1 μM), TAE684 (0.3 μM), lapatinib (0.1 μM) respectively for 6, 24, and 48 hrs. Expression of indicated proteins was assessed by immunoblots.

Article Snippet: BEZ235 (Dual PI3K/mTOR inhibitor), GSK1120212 (MEK inhibitor), PHA665752 (MET TKI), Erlotinib (EGFR TKI), Gefitinib (EGFR TKI) were purchased from Cayman Chemical.

Techniques: Expressing, Western Blot

Journal: Anti-cancer drugs

Article Title: Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase targeted therapy in lung and gastric cancer

doi: 10.1097/CAD.0000000000000561

Figure Lengend Snippet: Combination of Bcl-2/Bcl-xL inhibitor ABT-263 and a TKI is superior to the TKI alone. (A) Cell viability was determined after cells were treated as indicated for 72 hrs. Erlotinib, TAE684, Lapatinib, and ABT-263 were used at 1, 0.3, 0.1, and 1 μM respectively. Results shown are the mean ± SD. *p ˂0.02 compared with DMSO control. (B) Crystal violet staining of cells treated with DMSO or ABT-263 (1 μM) for 4 days, and TKI (1 μM erlotinib, 0.3 μM TAE684, 0.1 μM Lapatinib), or the combination of TKI and ABT-263 for 4 weeks. Representative results are shown.

Article Snippet: BEZ235 (Dual PI3K/mTOR inhibitor), GSK1120212 (MEK inhibitor), PHA665752 (MET TKI), Erlotinib (EGFR TKI), Gefitinib (EGFR TKI) were purchased from Cayman Chemical.

Techniques: Control, Staining